{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:47:09Z","timestamp":1779198429669,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.clinthera.2010.04.005","type":"journal-article","created":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T04:57:25Z","timestamp":1272603445000},"page":"637-648","source":"Crossref","is-referenced-by-count":48,"title":["Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: A retrospective, observational, sequential cohort analysis"],"prefix":"10.1016","volume":"32","author":[{"given":"David W.","family":"Kubiak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M.","family":"Bryar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne M.","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge O.","family":"Delgado-Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Mui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"MD","given":"Francisco M.","family":"Marty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.04.005_bib1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2010.04.005_bib2","doi-asserted-by":"crossref","first-page":"S487","DOI":"10.1093\/clinids\/17.Supplement_2.S487","article-title":"Emerging fungal pathogens in immunocompromised patients: Classification, diagnosis, and management","volume":"17","author":"Vartivarian","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2010.04.005_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000100055","article-title":"Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological malignancy","volume":"30","author":"Schuler","year":"2007","journal-title":"Onkologie"},{"key":"10.1016\/j.clinthera.2010.04.005_bib4","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2010.04.005_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever [published correction appears in N Engl J Med. 2007;356:760]","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2010.04.005_bib6","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2010.04.005_bib7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, doubleblind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2010.04.005_bib8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0002-9343(99)00457-X","article-title":"A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer","volume":"108","author":"Winston","year":"2000","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.04.005_bib9","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1086\/504492","article-title":"Pharmacology of systemic antifungal agents","volume":"43","author":"Dodds Ashley","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2010.04.005_bib10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejcsup.2007.06.005","article-title":"Empirical antifungal therapy in neutropaenic cancer patients with persistent fever","volume":"5","author":"Marchetti","year":"2007","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.clinthera.2010.04.005_bib11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/JCM.01901-07","article-title":"In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: Six years of global surveillance [published correction appears in J Clin Microbiol. 2008;46:3184-3185]","volume":"46","author":"Pfaller","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.clinthera.2010.04.005_bib12","series-title":"Cancidas (caspofungin acetate) [prescribing information].","year":"2010"},{"key":"10.1016\/j.clinthera.2010.04.005_bib13","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1128\/AAC.49.8.3317-3324.2005","article-title":"Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients","volume":"49","author":"Seibel","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2010.04.005_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2169\/internalmedicine.46.6021","article-title":"Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies","volume":"46","author":"Toubai","year":"2007","journal-title":"Intern Med"},{"key":"10.1016\/j.clinthera.2010.04.005_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2169\/internalmedicine.45.1498","article-title":"Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia","volume":"45","author":"Yanada","year":"2006","journal-title":"Intern Med"},{"key":"10.1016\/j.clinthera.2010.04.005_bib16","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2010.04.005_bib17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis [published correction appears in Clin Infect Dis. 2008;47:302]","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2010.04.005_bib18","series-title":"Presented at: 44th Annual Meeting of the Infectious Diseases Society of America","article-title":"Clinical and financial impact of adoption of micafungin as the preferred echinocandin in a university teaching hospital","author":"Lewis","year":"2006"},{"key":"10.1016\/j.clinthera.2010.04.005_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/510393","article-title":"Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship","volume":"44","author":"Dellit","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2010.04.005_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1399-3062.2006.00127.x","article-title":"Impact of alternate definitions of fever resolution on the composite endpoint in clinical trials of empirical antifungal therapy for neutropenic patients with persistent fever: Analysis of results from the Caspofungin Empirical Therapy Study","volume":"8","author":"de Pauw","year":"2006","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.clinthera.2010.04.005_bib21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2010.04.005_bib22","series-title":"Modern Epidemiology","author":"Rothman","year":"2008"},{"key":"10.1016\/j.clinthera.2010.04.005_bib23","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1345\/aph.1M237","article-title":"Echinocandins: The newest class of antifungals","volume":"43","author":"Sucher","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2010.04.005_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2010.04.005_bib25","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1097\/01.inf.0000245103.07614.e1","article-title":"The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants","volume":"25","author":"Heresi","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.clinthera.2010.04.005_bib26","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1128\/AAC.49.11.4536-4545.2005","article-title":"Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents","volume":"49","author":"Walsh","year":"2005","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810001293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810001293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T08:21:16Z","timestamp":1544516476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810001293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0149291810001293"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.04.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}